2021
Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis
Shafagati N, Stuver R, Boussi L, Koh M, Park A, Bain P, Foss F, Shen C, Jain S. Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis. Blood 2021, 138: 1431. DOI: 10.1182/blood-2021-150315.Peer-Reviewed Original ResearchOverall response rateT-cell lymphomaHistological subtypesNovel single agentsSingle agentHistone deacetylase inhibitorsConventional chemotherapyResponse rateCentral RegisterPartial responsePTCL-NOSClinical trialsChemotherapy agentsComparable overall response ratesGeneric inverse variance methodCutaneous T-cell lymphomaPhase IParticular histological subtypeSpeakers bureauCochrane Central RegisterProgression-free survivalMature T-cell lymphomasPI3K/Akt/mTORDuration of responseInverse variance methodNew nonchemotherapy treatment options for cutaneous T-cell lymphomas
Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Review Of Anticancer Therapy 2021, 21: 1017-1028. PMID: 33554707, DOI: 10.1080/14737140.2021.1882859.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeSézary syndromeMycosis fungoidesTreatment optionsNovel agentsCutaneous T-cell lymphomaCAR T-cell therapyAdditional novel agentsT-cell lymphomaT-cell therapyAntibody-based therapiesHistone deacetylase inhibitorsConventional chemotherapy approachesCheckpoint inhibitorsImmunomodulatory treatmentBrentuximab vedotinSystemic therapyAntibody agentsComplete responseLymph nodesTreatment armamentariumT cellsChemotherapy approachesImmune effectorsSmall molecule inhibitorsBelinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Hasal SJ, De Vos S, Oki Y, Deng C, Foss FM. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Experimental Hematology & Oncology 2021, 10: 15. PMID: 33602316, PMCID: PMC7893947, DOI: 10.1186/s40164-021-00203-8.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaOverall response rateT-cell lymphomaAdverse eventsDay 1Untreated peripheral T-cell lymphomaRefractory peripheral T-cell lymphomaMedian relative dose intensityPatient experienced DLTSafety/tolerabilityRelative dose intensityResultsTwenty-three patientsSerious adverse eventsFirst-line treatmentHistone deacetylase inhibitorsExperienced DLTsFebrile neutropeniaStandard CHOPStandard cyclophosphamideDose intensityAdditional patientsMTD doseCHOP combinationPK parametersSame dose
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategiesSynergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaB-cell lymphoma 2Advanced cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsHDAC inhibitionT-cell lymphoma patientsNovel BCL2 inhibitorPeripheral blood involvementAvailable systemic therapiesWorse clinical outcomesTreatment of patientsNon-Hodgkin lymphomaT-cell lymphomaCTCL cell linesPotential therapeutic targetHistone deacetylase inhibitionQuality of lifeHistone deacetylase inhibitorsBlood involvementSystemic therapyClinical outcomesTumor burdenLymphoma patientsCombination therapyBCL2 inhibitors
2016
Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 637-643. PMID: 27637428, DOI: 10.1016/j.clml.2016.08.009.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaFolliculotropic mycosis fungoidesPrevious systemic therapyMycosis fungoidesDisease involvementCutaneous tumorsTumor stageSystemic therapyRefractory cutaneous T-cell lymphomaSubtypes of CTCLSafety of romidepsinObjective response ratePhase II studyAggressive disease courseReview of diagnosisT-cell lymphomaHistone deacetylase inhibitorsII studyComposite endpointDisease courseHistology reportsClinical efficacyUncommon subtypeFavorable outcomePatientsRomidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal Of Hematology & Oncology 2016, 9: 22. PMID: 26965915, PMCID: PMC4785666, DOI: 10.1186/s13045-016-0243-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibiotics, AntineoplasticDepsipeptidesDisease ProgressionDisease-Free SurvivalDrug Administration ScheduleDrug Resistance, NeoplasmFatigueFemaleHistone Deacetylase InhibitorsHumansLymphoma, T-Cell, PeripheralMaleMiddle AgedNauseaNeoplasm Recurrence, LocalNeutropeniaRemission InductionTime FactorsTreatment OutcomeYoung AdultConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaStable diseaseT-cell lymphomaClinical benefitPivotal trialsCell lymphomaDay 1Good responseLong stable diseaseObjective response rateProgression-free survivalUnconfirmed complete responseT-cell malignanciesHistone deacetylase inhibitorsProlonged dosingDurable responsesMedian durationObjective responsePartial responseComplete responseCurrent therapiesProtocol amendmentCell malignanciesPatients
2015
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal Of Clinical Oncology 2015, 33: 2492-2499. PMID: 26101246, PMCID: PMC5087312, DOI: 10.1200/jco.2014.59.2782.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsDisease-Free SurvivalDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHistone Deacetylase InhibitorsHumansHydroxamic AcidsInfusions, IntravenousKaplan-Meier EstimateLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm Recurrence, LocalSulfonamidesTreatment OutcomeConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaInternational Working Group criteriaOverall response rateT-cell lymphomaPrior therapyOverall survivalGroup criteriaResponse rateEnd pointCommon grade 3Prior systemic therapyPrimary end pointSecondary end pointsNovel histone deacetylase inhibitorStem cell transplantationDuration of responseStandard of careDrug Administration approvalHistone deacetylase inhibitorsEvaluable patientsManageable toxicityAdverse eventsDurable responsesPartial responseRomidepsin for the Treatment of Peripheral T‐Cell Lymphoma
Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T‐Cell Lymphoma. The Oncologist 2015, 20: 1084-1091. PMID: 26099743, PMCID: PMC4571813, DOI: 10.1634/theoncologist.2015-0043.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaT-cell lymphomaHistone deacetylase inhibitorsPrior therapySpecialty centersTherapeutic approachesExpert hematopathologistsTreatment of PTCLDeacetylase inhibitorsPivotal phase II studiesCutaneous T-cell lymphomaPrior systemic therapyCommon adverse eventsObjective response ratePhase II studyFirst-line treatmentTreatment of patientsNon-Hodgkin lymphomaDifficulty of diagnosisAsthenic conditionsHeavy pretreatmentInduction chemotherapyAdvanced diseaseAdverse events
2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. Journal Of Hematology & Oncology 2014, 7: 11. PMID: 24456586, PMCID: PMC4016573, DOI: 10.1186/1756-8722-7-11.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibiotics, AntineoplasticCellulitisDepsipeptidesDisease-Free SurvivalDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHumansInfusions, IntravenousLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRemission InductionTime FactorsTreatment OutcomeVenous ThrombosisVomitingConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaCR/CRuDuration of responseObjective response rateT-cell lymphomaDurable responsesPrior therapySystemic therapyMedian DORMedian progression-free survivalCutaneous T-cell lymphomaReported safety profileProgression-free survivalUnconfirmed complete responseSubset of patientsLong-term responseIndependent review committeeTreatment of patientsSelective histone deacetylase inhibitorsHistone deacetylase inhibitorsLack of responseHeavy pretreatmentStable diseasePrimary endpoint
2013
Treatment strategies for peripheral T-cell lymphomas
Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAggressive first-line therapyAutologous stem cell transplantationConventional lymphoma therapyFirst-line therapyMajority of patientsStem cell transplantationSignal transduction inhibitorsHistone deacetylase inhibitorsFuture novel approachesLine therapyTransplant candidatesImproved survivalRelevant pathwaysAggressive diseaseCell transplantationInferior outcomesLymphoma therapyTransduction inhibitorsTreatment strategiesDeacetylase inhibitorsMonoclonal antibodiesMolecular profilingHeterogeneous group
2012
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal Of Clinical Oncology 2012, 30: 631-636. PMID: 22271479, DOI: 10.1200/jco.2011.37.4223.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibiotics, AntineoplasticDepsipeptidesDiarrheaDisease-Free SurvivalDrug Administration ScheduleFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm Recurrence, LocalPneumoniaTreatment OutcomeVascular DiseasesVomitingYoung AdultConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaPrior systemic therapyCR/CRuSystemic therapyT-cell lymphomaPrior therapyComplete response/unconfirmed complete responseResponse ratePrior stem cell transplantationEfficacy of romidepsinSingle-agent romidepsinObjective response ratePhase II studyPrimary end pointPhase II trialUnconfirmed complete responseStem cell transplantationIndependent review committeeDrug Administration approvalSelective histone deacetylase inhibitorsHistone deacetylase inhibitorsManageable toxicityII trialOpen label
2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapyPeripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biology
2010
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Lansigan F, Foss FM. Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma. Drugs 2010, 70: 273-286. PMID: 20166766, DOI: 10.2165/11532190-000000000-00000.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaMalignant T cellsTreatment strategiesT cellsManagement of CTCLPredictable adverse effectsRapid disease controlConservative treatment strategyFront-line therapyEarly-stage diseaseIndolent clinical courseMature T-cell lymphomasStem cell transplantInterleukin-2 receptorHistone deacetylase inhibitorsSystemic chemotherapyExtracorporeal photopheresisInitial managementSézary syndromeClinical courseCurative therapyBiological therapyCell transplantMycosis fungoides
2007
Mycosis Fungoides: Pathophysiology and Emerging Therapies
Duvic M, Foss FM. Mycosis Fungoides: Pathophysiology and Emerging Therapies. Seminars In Oncology 2007, 34: s21-s28. PMID: 18086343, DOI: 10.1053/j.seminoncol.2007.11.006.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesRefractory cutaneous T-cell lymphomaPrimary cutaneous T-cell lymphomaNeoplastic T lymphocytesSafe treatment strategyNon-Hodgkin lymphomaT-cell lymphomaLeukemic variant Sézary syndromeHistone deacetylase inhibitorsOrgan complicationsSystemic regimensCutaneous manifestationsEmerging TherapiesSézary syndromeSkin infiltrationSystemic therapyBiologic agentsCTCL subtypesTreatment strategiesCurrent treatmentT lymphocytesDeacetylase inhibitorsPurine nucleoside phosphorylase inhibitorTherapy
2004
Mycosis fungoides and the Sézary syndrome
Foss F. Mycosis fungoides and the Sézary syndrome. Current Opinion In Oncology 2004, 16: 421-428. PMID: 15314509, DOI: 10.1097/00001622-200409000-00002.Peer-Reviewed Original ResearchConceptsEarly-stage patientsSézary syndromeMycosis fungoidesTreatment paradigmPeptide-loaded dendritic cellsEvolution of immunotherapyUse of photopheresisClinical prognostic factorsNucleoside analogue therapyReceptor-directed therapyT cell responsesTreatment of patientsNon-Hodgkin lymphomaNovel treatment optionsFurther clinical evaluationNovel therapeutic approachesHistone deacetylase inhibitorsWorld Health OrganizationAnalogue therapySystemic therapyClinical stagingDendritic cellsPrognostic factorsSézary cellsClinical entity
2003
Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches
Foss F. Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches. Leukemia & Lymphoma 2003, 44: s55-s61. PMID: 15202526, DOI: 10.1080/10428190310001623757.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNovel agentsTherapeutic approachesAcute T-cell leukemia/lymphomaAdvanced refractory cutaneous T cell lymphomasEarly-stage cutaneous T-cell lymphomaMycosis fungoides/Sézary syndromeRefractory cutaneous T-cell lymphomaPeripheral T-cell lymphomaAllogeneic stem cell therapyT-cell leukemia/lymphomaDemonstrated survival benefitYear of diagnosisAdvanced-stage patientsCytokine receptor antagonistsProbability of progressionNovel therapeutic approachesLeukemia/lymphomaNew therapeutic approachesNF-kappaB inhibitorHistone deacetylase inhibitorsStem cell therapyCytotoxic regimensExtracutaneous disease